Goldman Sachs Upgrades Mid-America Apartment to Buy, Raises Price Target to $194
Goldman Sachs analyst Chandni Luthra upgrades Mid-America Apartment (NYSE:MAA) from Neutral to Buy and raises the price target from $178 to $194.
Argus Research Upgrades AT&T to Buy, Announces $24 Price Target
Argus Research analyst Joseph Bonner upgrades AT&T (NYSE:T) from Hold to Buy and announces $24 price target.
Maxim Group Upgrades NLS Pharmaceutics to Buy, Announces $4 Price Target
Maxim Group analyst Jason McCarthy upgrades NLS Pharmaceutics (NASDAQ:NLSP) from Hold to Buy and announces $4 price target.
BTIG Upgrades Avrobio to Buy, Announces $4 Price Target
BTIG analyst Yun Zhong upgrades Avrobio (NASDAQ:AVRO) from Neutral to Buy and announces $4 price target.
Goldman Sachs Upgrades American Homes 4 Rent to Buy, Raises Price Target to $39
Goldman Sachs analyst Chandni Luthra upgrades American Homes 4 Rent (NYSE:AMH) from Neutral to Buy and raises the price target from $36 to $39.
Argus Research Upgrades Allscripts Healthcare to Buy, Announces $26 Price Target
Argus Research analyst Jasper Hellweg upgrades Allscripts Healthcare (NASDAQ:MDRX) from Hold to Buy and announces $26 price target.
The SolarEdge Technologies Story ‘Looks Better Than We Thought’ Says Analyst
SolarEdge Technologies Inc (NASDAQ: SEDG) is in the spotlight as the U.S. increases pressure on Chinese companies moving products through other countries in Asia.
B of A Securities Upgrades SolarEdge Technologies to Buy, Raises Price Target to $367
B of A Securities analyst Julien Dumoulin-Smith upgrades SolarEdge Technologies (NASDAQ:SEDG) from Neutral to Buy and raises the price target from $269 to $367.
Raymond James Upgrades Tradeweb Markets to Outperform, Announces $74 Price Target
Raymond James analyst Patrick O'Shaughnessy upgrades Tradeweb Markets (NASDAQ:TW) from Market Perform to Outperform and announces $74 price target.
Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis
BTIG upgraded Aerovate Therapeutics Inc (NASDAQ:AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate’s…